These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 6421992)

  • 41. L-deprenyl therapy in Thai patients with Parkinson's disease: before and after, clinical trial of 50 patients.
    Poungvarin N; Viriyavejakul A
    J Med Assoc Thai; 1990 Jul; 73(7):381-6. PubMed ID: 2123233
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
    Csanda E; Tárczy M
    Acta Neurol Scand Suppl; 1983; 95():117-22. PubMed ID: 6428143
    [TBL] [Abstract][Full Text] [Related]  

  • 43. (-)Deprenyl in the treatment of Parkinson's disease.
    Birkmayer W; Riederer P; Youdim MB
    Clin Neuropharmacol; 1982; 5(2):195-230. PubMed ID: 6814755
    [No Abstract]   [Full Text] [Related]  

  • 44. Multicenter trial of L-Deprenyl in Parkinson disease.
    Ruggieri S; Denaro A; Meco G; Carta A; Stocchi F; Agnoli A
    Ital J Neurol Sci; 1986 Feb; 7(1):133-7. PubMed ID: 3082793
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
    Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overview of present day treatment of Parkinson's disease.
    Yahr MD
    J Neural Transm; 1978; 43(3-4):227-38. PubMed ID: 745015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
    Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
    N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
    [No Abstract]   [Full Text] [Related]  

  • 48. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J; Berstad J; Lien K
    Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
    Katzenschlager R; Head J; Schrag A; Ben-Shlomo Y; Evans A; Lees AJ;
    Neurology; 2008 Aug; 71(7):474-80. PubMed ID: 18579806
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deprenyl in Parkinson disease.
    Eisler T; Teräväinen H; Nelson R; Krebs H; Weise V; Lake CR; Ebert MH; Whetzel N; Murphy DL; Kopin IJ; Calne DB
    Neurology; 1981 Jan; 31(1):19-23. PubMed ID: 6161320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Deprenyl versus placebo in Parkinson disease: a double-blind study.
    Lieberman AN; Gopinathan G; Neophytides A; Foo SH
    N Y State J Med; 1987 Dec; 87(12):646-9. PubMed ID: 3124027
    [No Abstract]   [Full Text] [Related]  

  • 56. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
    Ann Neurol; 1998 Mar; 43(3):318-25. PubMed ID: 9506548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long term treatment with L-deprenyl.
    Birkmayer W
    J Neural Transm; 1978; 43(3-4):239-44. PubMed ID: 745016
    [No Abstract]   [Full Text] [Related]  

  • 59. (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.
    Birkmayer W; Knoll J; Riederer P; Youdim MB
    Mod Probl Pharmacopsychiatry; 1983; 19():170-6. PubMed ID: 6408405
    [No Abstract]   [Full Text] [Related]  

  • 60. Experiences with L-deprenyl in Parkinsonism.
    Csanda E; Antal J; Antóny M; Csanaky A
    J Neural Transm; 1978; 43(3-4):263-9. PubMed ID: 370348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.